pharmaceutical-jobs -- Biotechnology company Genzyme expects a new round of layoffs to result in charges of $16 million to $23 million. As far as the impact on biotech jobs is concerned, as per a Securities and Exchange Commission filing, the company is cutting 170 positions in the second phase of the layoff plan. The cuts include 60 unfilled positions and 40 jobs in San Diego, where it is closing a facility, reported the AP. The report added that Genzyme is offering severance packages to laid-off workers in the US and similar packages to employees outside the U.S. in accordance with local laws.
